FDA Grants Fast Track Status to Aktis Oncology’s Nectin-4 Radioconjugate for Advanced Bladder Cancer
Event summary
- FDA grants Fast Track designation to AKY-1189 for treating advanced urothelial cancer after prior therapies.
- AKY-1189 targets Nectin-4, expressed in 80-90% of urothelial cancer patients.
- Phase 1b trial (NCT07020117) ongoing for multiple Nectin-4 expressing tumors; preliminary results expected Q1 2027.
- Aktis’ miniprotein radioconjugate platform enables isotope-agnostic targeting of solid tumors.
The big picture
Aktis Oncology’s Fast Track designation underscores the growing strategic importance of targeted radiopharmaceuticals in oncology, particularly for hard-to-treat cancers like advanced urothelial carcinoma. The company’s miniprotein platform positions it to compete with existing radiopharmaceutical technologies, while its collaboration with Eli Lilly expands its development capabilities beyond its proprietary pipeline.
What we're watching
- Regulatory Advantage
- How Fast Track designation will accelerate AKY-1189’s development timeline and FDA review process.
- Clinical Validation
- Whether early Phase 1b data (due Q1 2027) will validate AKY-1189’s efficacy across multiple tumor types.
- Pipeline Expansion
- The pace at which Aktis advances its second program, AKY-2519, targeting B7-H3 expressing tumors.
Related topics